ID   MCC13
AC   CVCL_2583
SY   MCC13TC; MCC13 TC
DR   BioSample; SAMN07624419
DR   cancercelllines; CVCL_2583
DR   CBA; CBA-1338
DR   Cell_Model_Passport; SIDM00007
DR   Cosmic; 912929
DR   Cosmic; 1693075
DR   Cosmic; 1699815
DR   Cosmic; 2273913
DR   Cosmic-CLP; 1333003
DR   DepMap; ACH-001550
DR   ECACC; 10092302
DR   GDSC; 1333003
DR   IARC_TP53; 12477
DR   PharmacoDB; MCC13_889_2019
DR   PRIDE; PXD008181
DR   Wikidata; Q54904252
RX   PubMed=7814141;
RX   PubMed=8026890;
RX   PubMed=10732753;
RX   PubMed=11433400;
RX   PubMed=12209986;
RX   PubMed=12209990;
RX   PubMed=20444890;
RX   PubMed=22363598;
RX   PubMed=23563200;
RX   PubMed=30894373;
RX   PubMed=31889939;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Doubling time: 1 day (PubMed=20444890).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Pro (c.721T>C); ClinVar=VCV000376664; Zygosity=Heterozygous (PubMed=10732753; PubMed=23563200).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Ser (c.832C>T); ClinVar=VCV000376642; Zygosity=Heterozygous (PubMed=10732753; PubMed=23563200).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=0%; East Asian, South=1.16%; South Asian=3.02%; European, North=64.74%; European, South=31.08% (PubMed=30894373).
CC   Derived from site: Metastatic; Cervical lymph node; UBERON=UBERON_0002429.
ST   Source(s): CBA; DepMap
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 12
ST   D16S539: 9,11
ST   D18S51: 16,17
ST   D19S433: 15
ST   D21S11: 30,31
ST   D2S1338: 19,20
ST   D3S1358: 16,18
ST   D5S818: 9,12
ST   D7S820: 10
ST   D8S1179: 13,14
ST   FGA: 19,20
ST   Penta D: 13,14
ST   Penta E: 11,14
ST   TH01: 7,9.3
ST   TPOX: 8
ST   vWA: 17
DI   NCIt; C9231; Merkel cell carcinoma
DI   ORDO; Orphanet_79140; Cutaneous neuroendocrine carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   80Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 28
//
RX   PubMed=7814141; DOI=10.1002/ijc.2910600115;
RA   Leonard J.H., Dash P., Holland P., Kearsley J.H., Bell J.R.;
RT   "Characterisation of four Merkel cell carcinoma adherent cell lines.";
RL   Int. J. Cancer 60:100-107(1995).
//
RX   PubMed=8026890; DOI=10.1002/ijc.2910580223;
RA   Thomson J.A.F., Leonard J.H., McGregor K., Sturm R.A., Parsons P.G.;
RT   "A nonconsensus octamer-recognition sequence (TAATGARAT-motif)
RT   identifies a novel DNA binding protein in human Merkel cell carcinoma
RT   cell lines.";
RL   Int. J. Cancer 58:285-290(1994).
//
RX   PubMed=10732753; DOI=10.1054/bjoc.1999.1006;
RA   Van Gele M., Kaghad M., Leonard J.H., Van Roy N., Naeyaert J.M.,
RA   Geerts M.L., Van Belle S., Cocquyt V., Bridge J., Sciot R.,
RA   De Wolf-Peeters C., De Paepe A., Caput D., Speleman F.;
RT   "Mutation analysis of P73 and TP53 in Merkel cell carcinoma.";
RL   Br. J. Cancer 82:823-826(2000).
//
RX   PubMed=11433400; DOI=10.1002/ijc.1352;
RA   Cook A.L., Pollock P.M., Welch J., Walsh M.D., Bowman R.V.,
RA   Baumann K.C., Hayward N.K., Leonard J.H.;
RT   "CDKN2A is not the principal target of deletions on the short arm of
RT   chromosome 9 in neuroendocrine (Merkel cell) carcinoma of the skin.";
RL   Int. J. Cancer 93:361-367(2001).
//
RX   PubMed=12209986; DOI=10.1002/ijc.10554;
RA   Leonard J.H., Cook A.L., Van Gele M., Boyle G.M., Inglis K.J.,
RA   Speleman F., Sturm R.A.;
RT   "Proneural and proneuroendocrine transcription factor expression in
RT   cutaneous mechanoreceptor (Merkel) cells and Merkel cell carcinoma.";
RL   Int. J. Cancer 101:103-110(2002).
//
RX   PubMed=12209990; DOI=10.1002/ijc.10591;
RA   Van Gele M., Leonard J.H., Van Roy N., Van Limbergen H., Van Belle S.,
RA   Cocquyt V., Salwen H.R., De Paepe A., Speleman F.;
RT   "Combined karyotyping, CGH and M-FISH analysis allows detailed
RT   characterization of unidentified chromosomal rearrangements in Merkel
RT   cell carcinoma.";
RL   Int. J. Cancer 101:137-145(2002).
//
RX   PubMed=20444890; DOI=10.1128/JVI.02400-09;
RA   Houben R., Shuda M., Weinkam R., Schrama D., Feng H.-C., Chang Y.,
RA   Moore P.S., Becker J.C.;
RT   "Merkel cell polyomavirus-infected Merkel cell carcinoma cells require
RT   expression of viral T antigens.";
RL   J. Virol. 84:7064-7072(2010).
//
RX   PubMed=22363598; DOI=10.1371/journal.pone.0031255;
RA   Hafner C., Houben R., Baeurle A., Ritter C., Schrama D.,
RA   Landthaler M., Becker J.C.;
RT   "Activation of the PI3K/AKT pathway in Merkel cell carcinoma.";
RL   PLoS ONE 7:E31255-E31255(2012).
//
RX   PubMed=23563200; DOI=10.1038/jid.2013.169;
RA   Houben R., Dreher C., Angermeyer S., Borst A., Utikal J.S.,
RA   Haferkamp S., Peitsch W.K., Schrama D., Hesbacher S.;
RT   "Mechanisms of p53 restriction in Merkel cell carcinoma cells are
RT   independent of the Merkel cell polyoma virus T antigens.";
RL   J. Invest. Dermatol. 133:2453-2460(2013).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31889939; DOI=10.1186/s12014-019-9263-z;
RA   Kotowski U., Erovic B.M., Schnoll J., Stanek V., Janik S., Steurer M.,
RA   Mitulovic G.;
RT   "Quantitative proteome analysis of Merkel cell carcinoma cell lines
RT   using SILAC.";
RL   Clin. Proteomics 16:42.1-42.13(2019).
//